Benzinga | Dec 13, 2021 07:19AM EST

Agios Announces Data From Investigator-led Studies Of Mitapivat In Adults With Sickle Cell Disease Demonstrating Improvements In Anemia, Hemolysis And Sickling Parameters At 63rd ASH Annual Meeting And Exposition

-- Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients --



-- Safety Profile Consistent with Previously Reported Clinical Data --

-- Agios Announces Initiation of Phase 2/3 RISE UP Study of Mitapivat in Adults with Sickle Cell Disease --

-- Agios to Host Investor Webcast on Dec. 14, 2021, at 7:30 a.m. ET --